Alantos Joins DPP-4 Hunt With Help From France’s Servier
This article was originally published in The Pink Sheet Daily
Executive Summary
The Cambridge, Mass. company is touting its “second generation” dipeptidyl peptidase-4 inhibitor, headed for Phase II in the first quarter of 2007, as “a superior molecule to both Galvus and Januvia” for treatment of type 2 diabetes.